Sign up to save your podcasts
Or
Share Computer Vision - Multimodal Doctor-in-the-Loop A Clinically-Guided Explainable Framework for Predicting Pathological Response in Non-Small Cell Lung Cancer
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Computer Vision - Multimodal Doctor-in-the-Loop A Clinically-Guided Explainable Framework for Predicting Pathological Response in Non-Small Cell Lung Cancer
Alright learning crew, Ernis here, ready to dive into another fascinating paper for your listening pleasure! Today, we're tackling a study that aims to improve how doctors predict whether lung cancer treatment will actually work for patients before they even start.
Now, we're talking about non-small cell lung cancer (NSCLC), which is, unfortunately, the most common type of lung cancer. The researchers focused on what's called neoadjuvant therapy – that's treatment, like chemotherapy or radiation, given before surgery to shrink the tumor and make it easier to remove. The big question is: how do we know ahead of time if this pre-surgery treatment will actually be effective?
Traditionally, doctors have relied on things like radiomics, which is basically extracting a bunch of features from medical images (like CT scans) to try and predict how the tumor will respond. It's like trying to judge a book by its cover, but instead of judging a novel, it's judging a cancerous tumor. However, radiomics and older AI methods aren't always accurate.
Here's where things get interesting. This study uses something called Multimodal Deep Learning. Think of it like this: instead of just looking at the cover of the book (the images), you're also getting the author's notes, reviews, and maybe even a sneak peek at a few chapters. In this case, the "cover" is the medical imaging data, and the "author's notes" are the patient's clinical data, like their age, medical history, and other lab results. By combining these different "modes" of information, the AI can get a much more complete picture.
But wait, there's more! The researchers also incorporated eXplainable Artificial Intelligence (XAI). This is crucial because we don't just want the AI to tell us if the treatment will work; we want to know why. It's like having the AI explain its reasoning, showing us which parts of the images and clinical data were most important in its prediction. This helps doctors understand the AI's decision-making process and build trust in its predictions.
The researchers used an intermediate fusion strategy. Imagine you're baking a cake. Instead of adding all the ingredients at the very beginning or the very end, you mix some ingredients early on, then add others later. This "intermediate fusion" allows the imaging and clinical data to interact with each other in a more meaningful way, improving the AI's performance.
And here's the really cool part: they developed a Multimodal Doctor-in-the-Loop method. This is where the doctors themselves get involved in training the AI. Think of it as the AI learning from a seasoned expert. The doctors guide the AI's attention, starting with the broader lung regions and gradually focusing on the specific lesions. It's like the doctor is saying, "Hey AI, pay attention to this area – it's really important!"
So, what did they find? The results showed that this new method improved both the accuracy of the predictions and the explainability. The AI was better at predicting whether the treatment would work, and it could also explain why it made that prediction. This is a big deal because it could help doctors personalize treatment plans for lung cancer patients, potentially leading to better outcomes and fewer unnecessary treatments.
Why should you care?
This study raises some interesting questions:
Food for thought, learning crew. Until next time, keep those neurons firing!
Credit to Paper authors: Alice Natalina Caragliano, Claudia Tacconi, Carlo Greco, Lorenzo Nibid, Edy Ippolito, Michele Fiore, Giuseppe Perrone, Sara Ramella, Paolo Soda, Valerio Guarrasi
View all episodes
By ernestasposkusAlright learning crew, Ernis here, ready to dive into another fascinating paper for your listening pleasure! Today, we're tackling a study that aims to improve how doctors predict whether lung cancer treatment will actually work for patients before they even start.
Now, we're talking about non-small cell lung cancer (NSCLC), which is, unfortunately, the most common type of lung cancer. The researchers focused on what's called neoadjuvant therapy – that's treatment, like chemotherapy or radiation, given before surgery to shrink the tumor and make it easier to remove. The big question is: how do we know ahead of time if this pre-surgery treatment will actually be effective?
Traditionally, doctors have relied on things like radiomics, which is basically extracting a bunch of features from medical images (like CT scans) to try and predict how the tumor will respond. It's like trying to judge a book by its cover, but instead of judging a novel, it's judging a cancerous tumor. However, radiomics and older AI methods aren't always accurate.
Here's where things get interesting. This study uses something called Multimodal Deep Learning. Think of it like this: instead of just looking at the cover of the book (the images), you're also getting the author's notes, reviews, and maybe even a sneak peek at a few chapters. In this case, the "cover" is the medical imaging data, and the "author's notes" are the patient's clinical data, like their age, medical history, and other lab results. By combining these different "modes" of information, the AI can get a much more complete picture.
But wait, there's more! The researchers also incorporated eXplainable Artificial Intelligence (XAI). This is crucial because we don't just want the AI to tell us if the treatment will work; we want to know why. It's like having the AI explain its reasoning, showing us which parts of the images and clinical data were most important in its prediction. This helps doctors understand the AI's decision-making process and build trust in its predictions.
The researchers used an intermediate fusion strategy. Imagine you're baking a cake. Instead of adding all the ingredients at the very beginning or the very end, you mix some ingredients early on, then add others later. This "intermediate fusion" allows the imaging and clinical data to interact with each other in a more meaningful way, improving the AI's performance.
And here's the really cool part: they developed a Multimodal Doctor-in-the-Loop method. This is where the doctors themselves get involved in training the AI. Think of it as the AI learning from a seasoned expert. The doctors guide the AI's attention, starting with the broader lung regions and gradually focusing on the specific lesions. It's like the doctor is saying, "Hey AI, pay attention to this area – it's really important!"
So, what did they find? The results showed that this new method improved both the accuracy of the predictions and the explainability. The AI was better at predicting whether the treatment would work, and it could also explain why it made that prediction. This is a big deal because it could help doctors personalize treatment plans for lung cancer patients, potentially leading to better outcomes and fewer unnecessary treatments.
Why should you care?
This study raises some interesting questions:
Food for thought, learning crew. Until next time, keep those neurons firing!
Credit to Paper authors: Alice Natalina Caragliano, Claudia Tacconi, Carlo Greco, Lorenzo Nibid, Edy Ippolito, Michele Fiore, Giuseppe Perrone, Sara Ramella, Paolo Soda, Valerio Guarrasi